




PHARMACEUTICAL 2022

Corvus Pharmaceuticals Inc.
Rank 135 of 466





PHARMACEUTICAL 2022

Corvus Pharmaceuticals Inc.
Rank 135 of 466

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 205%, being 127% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	71,312
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,692
Liabilities, Non-Current	2,601
Other Assets	37,692
Other Compr. Net Income	1,865
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,611
Other Revenues	0
Property and Equipment	451
Research and Development	29,115
Selling, General and Administrative Expense	9,515

Output Variable	Value in 1000 USD
Assets	109,455
Liabilities	12,293
Expenses	38,630
Revenues	0
Stockholders Equity	97,162
Net Income	-43,241
Comprehensive Net Income	-42,308
Economic Capital Ratio	205%